HOWL
Werewolf Therapeutics, Inc. · Healthcare · Market cap $45.1M(Price slightly stale)
Insiders sold $2.1M net in the last 90 days ·2 sellers, 0 buyers· 29 of 42 sales under Rule 10b5-1 plans· latest Form 4 filed Jul 8, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$8.7M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Jul 8, 2026
EVNIN LUKE
Werewolf Therapeutics, Inc. (HOWL) has 53 SEC Form 4 filings (163 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Jul 8, 2026.
Inside the rolling window, 4 insiders at Werewolf Therapeutics, Inc. reported no open-market purchases and 153 open-market sales totaling $8.7M. The most active filer is Director EVNIN LUKE with 87 filings. Insiders have net sold $2.3M over the trailing 6 months. The most recent open-market filing is a sale of 35,770 shares by Director EVNIN LUKE, dated Jul 6, 2026, worth $11K.
- Industry:Biotechnology
- CEO:Daniel J. Hicklin
- Employees:39
- HQ:Watertown, MA, US
- IPO:2021-04-30
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Director | Sale | 35,770 | $11K | Jul 8 | +157.8% | SEC ↗ | |
| Director | Sale | 107,429 | $33K | Jul 8 | +157.8% | SEC ↗ | |
| Director | Sale | 157,084 | $47K | Jun 29 | +201.3% | SEC ↗ | |
| 10% Owner | Sale | 416,911 | $146K | Jun 22 | +150.8% | SEC ↗ | |
| 10% Owner | Sale | 170,441 | $68K | Jun 16 | +157.8% | SEC ↗ | |
| 10% Owner | Sale | 128,770 | $50K | Jun 16 | +157.8% | SEC ↗ | |
| 10% Owner | Sale | 149,625 | $55K | Jun 16 | +157.8% | SEC ↗ | |
| 10% Owner | Sale | 369,800 | $137K | Jun 12 | — | SEC ↗ | |
| 10% Owner | Sale | 45,923 | $17K | Jun 12 | — | SEC ↗ | |
| 10% Owner | Sale | 262,503 | $100K | Jun 12 | — | SEC ↗ | |
| Director | Sale | 76,928 | $28K | Jun 10 | — | SEC ↗ | |
| Director | Sale | 20,072 | $9K | Jun 8 | — | SEC ↗ | |
| Director | Sale | 24,946 | $10K | Jun 8 | — | SEC ↗ | |
| Director | Sale | 60,547 | $24K | Jun 8 | — | SEC ↗ | |
| Director | Sale | 80,459 | $38K | Jun 3 | — | SEC ↗ | |
| Director | Sale | 29,595 | $13K | Jun 3 | — | SEC ↗ | |
| Director | Sale | 29,749 | $12K | Jun 3 | — | SEC ↗ | |
| Director | Sale | 80,852 | $39K | May 29 | — | SEC ↗ | |
| Director | Sale | 27,698 | $13K | May 29 | — | SEC ↗ | |
| Director | Sale | 32,556 | $15K | May 29 | — | SEC ↗ | |
| Director | Sale | 36,387 | $15K | May 26 | — | SEC ↗ | |
| Director | Sale | 87,425 | $39K | May 26 | — | SEC ↗ | |
| Director | Sale | 67,950 | $32K | May 26 | — | SEC ↗ | |
| Director | Sale | 22,184 | $11K | May 20 | — | SEC ↗ | |
| Director | Sale | 62,970 | $28K | May 20 | — | SEC ↗ |
Earnings: last 7 quarters
Frequently asked questions
How many SEC Form 4 insider filings does HOWL have?
Werewolf Therapeutics, Inc. (HOWL) has 53 SEC Form 4 filings (163 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Jul 8, 2026.
When was the most recent SEC Form 4 filing for HOWL?
The most recent Form 4 filing for HOWL on Tracefour is dated Jul 8, 2026.
Who is the most active insider at HOWL?
The most active SEC Form 4 filer at HOWL in the rolling window is Director EVNIN LUKE, with 87 filings.
What is the net insider flow at HOWL over the last 6 months?
Over the trailing 180 days, insiders at HOWL have net sold $2.3M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at HOWL in the current window?
Inside the rolling window, insiders at HOWL bought $0 and sold $8.7M based on SEC Form 4 filings.
Can I get alerts for HOWL insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Werewolf Therapeutics, Inc. (HOWL). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Werewolf Therapeutics, Inc. is in the Healthcare sector.